Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.5.4.1 - cytosine deaminase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (Macaca leonina) That May Reduce APOBEC3G-Mediated Hypermutation Pressure on HIV-1.
APOBEC3-Mediated Editing in HIV Type 1 from Pediatric Patients and Its Association with APOBEC3G/CUL5 Polymorphisms and Vif Variability.
APOBEC3G genetic variants and their influence on the progression to AIDS.
APOBEC3G levels predict rates of progression to AIDS.
APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host.
APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso.
Association of single nucleotide polymorphisms of APOBEC3G with susceptibility to HIV-1 infection and disease progression among men engaging in homosexual activity in northern China.
Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms.
Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys.
Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G.
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.
Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
The Battle between Retroviruses and APOBEC3 Genes: Its Past and Present.
Vif hijacks CBF-? to degrade APOBEC3G and promote HIV-1 infection.
Adenocarcinoma
5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.
Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-? Against Lymph Node-derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models.
Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression.
Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.
The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells.
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.
Treatment of human tumor cells by combine gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and bacterial cytosine deaminase suicide gene.
Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.
Adenocarcinoma of Lung
APOBEC1 cytosine deaminase activity on single-stranded DNA is suppressed by replication protein A.
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.
Anemia
Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.
Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.
Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins.
Arthritis
Small ruminant lentiviral Vif proteins commonly utilize cyclophilin A, an evolutionarily and structurally conserved protein, to degrade ovine and caprine APOBEC3 proteins.
Atherosclerosis
Epac1 (Exchange Protein Directly Activated by cAMP 1) Upregulates LOX-1 (Oxidized Low-Density Lipoprotein Receptor 1) to Promote Foam Cell Formation and Atherosclerosis Development.
Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.
High-resolution genetic mapping in the diversity outbred mouse population identifies Apobec1 as a candidate gene for atherosclerosis.
Barrett Esophagus
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.
Brain Neoplasms
Adenosine potentiates the therapeutic effects of neural stem cells expressing cytosine deaminase against metastatic brain tumors.
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes.
Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells.
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.
Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine.
Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases.
In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus.
Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells.
Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells.
The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase.
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
[Antineoplastic effect of 5-fluorocytosine and cytosine deaminase on brain tumor (author's transl)]
Breast Neoplasms
207 engineered human amniotic fluid-derived stem cells by expressing Cytosine deaminase (cd) and thymidine kinase (hsv-tk) mediate targeting killing effect in breast cancer cells.
A Common Deletion in the APOBEC3 Genes and Breast Cancer Risk.
Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer.
Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
APOBEC3 deletion increases the risk of breast cancer: a meta-analysis.
APOBEC3 Deletion is Associated with Breast Cancer Risk in a Sample of Southeast Iranian Population.
APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.
APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women.
APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response.
APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
Association of APOBEC3 deletion with cancer risk: A meta-analysis of 26 225 cases and 37 201 controls.
Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells.
Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Connexin-43 Enhances the Redesigned Cytosine Deaminase Activity for Suicide Gene Therapy in Human Breast Cancer Cells.
Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients.
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.
Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase.
Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation.
Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.
Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models.
Image-guided enzyme/prodrug cancer therapy.
Inhibition of the aberrant A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop attenuated malignant biological behaviors of glioma cells.
Intratumoral gene transfer of the Cytosine deaminase gene for the treatment of breast cancer.
iPS-derived MSCs from an expandable bank to deliver a prodrug-converting enzyme that limits growth and metastases of human breast cancers.
Nanoplex Delivery of siRNA and Prodrug Enzyme for Multimodality Image-Guided Molecular Pathway Targeted Cancer Therapy.
Non-viral Suicide Gene Therapy: Cytosine Deaminase Gene Directed by VEGF Promoter and 5-fluorocytosine as a Gene Directed Enzyme/prodrug System in Breast Cancer Model.
Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture.
Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations.
Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models.
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer.
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell apoptosis in breast cancer cells.
Carcinogenesis
APOBEC-mediated DNA alterations: A possible new mechanism of carcinogenesis in EBV-positive gastric cancer.
APOBEC3 genes: retroviral restriction factors to cancer drivers.
Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like family genes activation and regulation during tumorigenesis.
Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression.
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.
DNA deamination in immunity.
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples.
Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia.
Mouse APOBEC1 cytidine deaminase can induce somatic mutations in chromosomal DNA.
Phosphorylation Directly Regulates the Intrinsic DNA Cytidine Deaminase Activity of Activation-induced Deaminase and APOBEC3G Protein.
Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B.
The rabbit as an orthologous small animal model for APOBEC3A oncogenesis.
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.
The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.
Understanding the regulation of APOBEC3 expression: Current evidence and much to learn.
[APOBEC3s: history of an antiviral and mutagenic protein family].
Carcinoma
A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy.
Activation of the CMV-IE promoter by hyperthermia in vitro and in vivo: biphasic heat induction of cytosine deaminase suicide gene expression.
Adenovirus-mediated gene transfer in the treatment of pancreatic cancer.
Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma.
Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer.
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
APOBEC1 complementation factor facilitates cell migration by promoting nucleus translocation of SMAD3 in renal cell carcinoma cells.
APOBEC3B Activity Is Prevalent in Urothelial Carcinoma Cells and Only Slightly Affected by LINE-1 Expression.
APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma.
APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis.
Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition.
Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.
Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.
Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma.
Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model.
Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
Expression of Cytosine Deaminase Gene in Human Colon Carcinoma Cells by Recombinant Retroviral Vector.
Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase.
Genetic immunotherapy for hepatocellular carcinoma by endothelial progenitor cells armed with cytosine deaminase.
In vitro and in vivo effect of 5-FC combined gene therapy with TNF-? and CD suicide gene on human laryngeal carcinoma cell line Hep-2.
In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Inhibitory effect of therapeutic genes, cytosine deaminase and interferon??, delivered by genetically engineered stem cells against renal cell carcinoma.
Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G.
Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma.
Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine.
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Radiosensitization and Anti-tumour Effects of Cytosine Deaminase and Thymidine Kinase Fusion Suicide Gene in Human Adenoid Cystic Carcinoma Cells.
Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver.
Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response.
[Anticancer efficacy of combining cytosine deaminase/5-fluorocytosine gene therapy and radiotherapy on cervical carcinoma]
[Experimental study on human pancreatic carcinoma treated by cytosine deaminase gene therapy]
[The killing effects of two prodrug sensitivity genes on human pancreatic carcinoma cells PC-2]
Carcinoma, Adenoid Cystic
Radiosensitization and Anti-tumour Effects of Cytosine Deaminase and Thymidine Kinase Fusion Suicide Gene in Human Adenoid Cystic Carcinoma Cells.
Carcinoma, Ductal
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
Carcinoma, Hepatocellular
A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.
Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels.
APOBEC-mediated interference with hepadnavirus production.
APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma.
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma.
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.
Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma.
Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy.
Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice.
Cytotoxic effect of a replication-incompetent adenoviral vector with cytosine deaminase gene driven by L-plastin promoter in hepatocellular carcinoma cells.
DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B.
Endothelial Progenitor Cells Combined with Cytosine Deaminase-Endostatin for Suppression of Liver Carcinoma.
Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies.
Gene therapy for human hepatocellular carcinoma with cytosine deaminase gene and prodrug flucytosine.
Gene Therapy with Cytosine Deaminase and Endostatin Fusion Gene Mediated by Endothelial Progenitor Cells in Hepatomas.
Genetic immunotherapy for hepatocellular carcinoma by endothelial progenitor cells armed with cytosine deaminase.
Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations.
High expression of APOBEC3G in patients infected with hepatitis C virus.
Human Sulfatase-1 Improves the Effectiveness of Cytosine Deaminase Suicide Gene Therapy with 5-Fluorocytosine Treatment on Hepatocellular Carcinoma Cell Line HepG2 In Vitro and In Vivo.
In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene.
Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.
N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Non-lytic Lymphocytes Engineered to Express Virus-specific T-cell Receptors Limit HBV Infection by Activating APOBEC3.
Overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-related hepatocellular carcinoma.
Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model.
Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells.
The RNA-editing enzyme APOBEC1 requires heterogeneous nuclear ribonucleoprotein Q isoform 6 for efficient interaction with interleukin-8 mRNA.
[Expression and subcellular localization of APOBEC3G in peripheral blood mononuclear cells and liver tissues of chronic HBV patients]
Carcinoma, Intraductal, Noninfiltrating
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
Carcinoma, Lewis Lung
Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition.
Carcinoma, Non-Small-Cell Lung
Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Combination therapy in A549 cells.
Carcinoma, Ovarian Epithelial
APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women.
Carcinoma, Renal Cell
APOBEC1 complementation factor facilitates cell migration by promoting nucleus translocation of SMAD3 in renal cell carcinoma cells.
Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.
Expression of APOBEC3G in kidney cells.
Inhibitory effect of therapeutic genes, cytosine deaminase and interferon??, delivered by genetically engineered stem cells against renal cell carcinoma.
Carcinoma, Squamous Cell
Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Therapeutic effect of AdCMVCD/5-FC system and metabolism of 5-FC in the treatment of human tongue squamous cell carcinoma.
Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response.
Cervical Intraepithelial Neoplasia
APOBEC3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression.
Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.
Chickenpox
Foreword.
Metabolic suicide genes in gene therapy.
Cholangiocarcinoma
Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells.
Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models.
Cholelithiasis
Investigation of the Lith6 candidate genes APOBEC1 and PPARG in human gallstone disease.
Choriocarcinoma
Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-? Against Choriocarcinoma in Xenografted Metastatic Mouse Models.
Coinfection
HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso.
Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
Colonic Neoplasms
A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy.
Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer.
Antitumor Therapy Mediated by 5-Fluorocytosine and a Recombinant Fusion Protein Containing TSG-6 Hyaluronan Binding Domain and Yeast Cytosine Deaminase.
APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis.
CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter.
Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine.
Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.
Enzyme/prodrug gene therapy for human colon cancer cells using adenovirus-mediated transfer of the Escherichia coli cytosine deaminase gene driven by a CAG promoter associated with 5-fluorocytosine administration.
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model.
Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver.
Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
[Efficacy of antitumour colon cancer cell vaccine modified by eschrichia coli cytosine deaminase gene]
[Experimental studies on the treatment of colon cancer by cytosine deaminase gene and 5-fluorocytosine]
[Hyperthermia enhanced the killing effect of 5-fluorocytosine on human colon cancer cell line transfected with cytosine deaminase gene]
Colorectal Neoplasms
A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.
A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.
Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy.
Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells.
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis.
Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer.
Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter.
High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer.
In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Integrative analysis of significant RNA-binding proteins in colorectal cancer metastasis.
Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase - for colorectal cancer.
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene.
Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene.
Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene.
Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-? via their tumor-tropic effect in cellular and xenograft mouse models.
Tumor-specific chemo-radio-gene therapy for colorectal cancer cells using adenovirus vector expressing the cytosine deaminase gene.
Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
[Hyperthermia enhanced the killing effect of 5-fluorocytosine on human colon cancer cell line transfected with cytosine deaminase gene]
[In vitro antitumor effect of adenovirus containing CD-TK fusion gene driven by VEGF promoter on LoVo cells]
[X-ray combined with cytosine deaminase suicide gene therapy enhances killing of colorectal carcinoma cells in vitro]
Condylomata Acuminata
Heat-Induced Editing of HPV Genes to Clear Mucocutaneous Warts?
Coronary Artery Disease
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Coronavirus Infections
The substitution spectra of coronavirus genomes.
COVID-19
Differentially expressed immune response genes in COVID-19 patients based on disease severity.
Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants.
Cystadenocarcinoma, Serous
[Anticancer effects of cytosine deaminase gene/5-fluorocytosine therapies to ovarian cancer in vivo]
Cystic Fibrosis
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
cytidine deaminase deficiency
Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability.
cytosine deaminase deficiency
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo.
Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability.
Diabetic Nephropathies
Augmenting podocyte injury promotes advanced diabetic kidney disease in Akita mice.
Diphtheria
Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Dyslipidemias
Systems analysis of small signaling modules relevant to eight human diseases.
Encephalitis
Increased APOBEC3G expression is associated with extensive G-to-A hypermutation in viral DNA in rhesus macaque brain during lentiviral infection.
Small ruminant lentiviral Vif proteins commonly utilize cyclophilin A, an evolutionarily and structurally conserved protein, to degrade ovine and caprine APOBEC3 proteins.
Endometrial Neoplasms
205 selective antitumor therapeutic effect of 5-fluorocytosine and interferon-Beta against breast and endometrial cancer cells by engineered stem cells expressing Cytosine deaminase and human interferon-Beta.
Antitumor Therapeutic Effects of Cytosine Deaminase and Interferon-{beta} Against Endometrial Cancer Cells Using Genetically Engineered Stem Cells In Vitro.
High APOBEC1 Complementation Factor Expression Positively Modulates the Proliferation, Invasion, and Migration of Endometrial Cancer Cells Through Regulating P53/P21 Signaling Pathway.
Epilepsy
A Novel RNA Editing Sensor Tool and a Specific Agonist Determine Neuronal Protein Expression of RNA-Edited Glycine Receptors and Identify a Genomic APOBEC1 Dimorphism as a New Genetic Risk Factor of Epilepsy.
Corrigendum: A Novel RNA Editing Sensor Tool and a Specific Agonist Determine Neuronal Protein Expression of RNA-Edited Glycine Receptors and Identify a Genomic APOBEC1 Dimorphism as a New Genetic Risk Factor of Epilepsy.
Epstein-Barr Virus Infections
APOBEC-mediated DNA alterations: A possible new mechanism of carcinogenesis in EBV-positive gastric cancer.
EBV in T-/NK-Cell Tumorigenesis.
Equine Infectious Anemia
Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.
Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.
Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins.
Esophageal Squamous Cell Carcinoma
Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G.
Extranodal Extension
Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
Fibrosarcoma
Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.
Foot-and-Mouth Disease
Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging.
Gallstones
Investigation of the Lith6 candidate genes APOBEC1 and PPARG in human gallstone disease.
Glioblastoma
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.
Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models.
Stem cell based glioblastoma gene therapy.
Glioma
5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon.
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.
Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus.
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model.
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.
Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients.
Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors.
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma.
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine.
Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene.
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.
MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.
Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier.
Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells.
The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.
The enhanced efficacy of herpes simplex virus by lentivirus mediated VP22 and cytosine deaminase gene therapy against glioma.
Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma.
Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells.
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy.
[Experimental treatment of brain tumor cells using CD suicide gene]
Gliosarcoma
Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Head and Neck Neoplasms
Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.
Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase.
HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer.
Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation.
Hemoglobin SC Disease
Differentially expressed immune response genes in COVID-19 patients based on disease severity.
Hepatitis
Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.
Genetic and in vitro assays of DNA deamination.
[Expression and subcellular localization of APOBEC3G in peripheral blood mononuclear cells and liver tissues of chronic HBV patients]
Hepatitis B
A3G-induced mutations show low prevalence and exhibit plus strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.
APOBEC-mediated interference with hepadnavirus production.
APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo.
APOBEC3-mediated restriction of RNA virus replication.
APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G.
APOBEC3G & HTLV-1: inhibition without deamination.
APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems.
APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma.
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma.
Characterization of APOBEC3G binding to 7SL RNA.
Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications.
Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B.
Different antiviral activities of natural APOBEC3C, APOBEC3G, and APOBEC3H variants against hepatitis B virus.
Dual effect of APOBEC3G on Hepatitis B virus.
Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro.
Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection.
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.
Full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B.
G to A hypermutation of TT virus.
Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
Hepatitis B virus X protein is capable of down-regulating protein level of host antiviral protein APOBEC3G.
Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
High expression of APOBEC3G in patients infected with hepatitis C virus.
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H.
Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection.
Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.
Inhibition of hepatitis B virus replication by APOBEC3G.
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis.
N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Population stratification of a common APOBEC gene deletion polymorphism.
Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells.
Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids.
Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis.
Small-molecule inhibition of HIV-1 Vif.
STAT1-Independent Cell Type-Specific Regulation of Antiviral APOBEC3G by IFN-{alpha}.
The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses.
The potential role of APOBEC3G in limiting replication of hepatitis B virus.
[Inhibition of hepatitis B and duck hepatitis B virus replication by APOBEC3G]
Hepatitis B, Chronic
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma.
Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.
Interferon-alpha Induces High Expression of APOBEC3G and STAT-1 in Vitro and in Vivo.
Polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population.
[Expression and subcellular localization of APOBEC3G in peripheral blood mononuclear cells and liver tissues of chronic HBV patients]
Hepatitis C
High expression of APOBEC3G in patients infected with hepatitis C virus.
Hepatitis C, Chronic
High expression of APOBEC3G in patients infected with hepatitis C virus.
Hepatitis, Chronic
High expression of APOBEC3G in patients infected with hepatitis C virus.
[Association between APOBEC3G polymorphisms and susceptibility to chronic hepatitis B].
Herpes Simplex
207 engineered human amniotic fluid-derived stem cells by expressing Cytosine deaminase (cd) and thymidine kinase (hsv-tk) mediate targeting killing effect in breast cancer cells.
A dual drug sensitive L. major induces protection without lesion in C57BL/6 mice.
A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma.
A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy.
A potential therapeutic strategy to combat leukemia virus infection.
A preliminary study on the construction of double suicide gene delivery vectors by mesenchymal stem cells and the in vitro inhibitory effects on SKOV3 cells.
Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity.
Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells.
Adenovirus-mediated targeted gene therapy for breast cancer and for purging hematopoietic stem-cell sources.
Advances in Imaging Gene-Directed Enzyme Prodrug Therapy.
Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
Bystander or no bystander for gene directed enzyme prodrug therapy.
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes.
Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma.
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.
Computational modeling and functional analysis of Herpes simplex virus type-1 thymidine kinase and Escherichia coli cytosine deaminase fusion protein.
Current progress in suicide gene therapy for cancer.
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo.
Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model.
Dual-vector prodrug activator gene therapy using retroviral replicating vectors.
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.
Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression.
Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene.
Foreword.
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.
Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity.
Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo.
GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo.
Highly efficient gene transfer to solid tumors in vivo by tumor-selective replicating retrovirus vectors.
Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models.
Imaging methods in gene therapy of cancer.
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models.
Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy.
Killing effect of coexpressing cytosine deaminase and thymidine kinase on rat vascular smooth muscle cells.
Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase.
Metabolic suicide genes in gene therapy.
Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells.
Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination.
Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Procaspase-3 enhances the in vitro effect of cytosine deaminase-thymidine kinase disuicide gene therapy on human ovarian cancer.
Quantitative evaluation and comparison of two prodrug-activating suicide gene therapies on oral squamous cell carcinoma.
Radiosensitization and Anti-tumour Effects of Cytosine Deaminase and Thymidine Kinase Fusion Suicide Gene in Human Adenoid Cystic Carcinoma Cells.
Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy.
Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.
Reversibly immortalized hepatic progenitor cell line containing double suicide genes.
Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
Simultaneous Cre catalyzed recombination of two alleles to restore neomycin sensitivity and facilitate homozygous mutations.
Suicide gene therapy using E. coli beta-galactosidase.
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell.
The enhanced efficacy of herpes simplex virus by lentivirus mediated VP22 and cytosine deaminase gene therapy against glioma.
Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.
Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review.
[Antitumor effects of cytosine deaminase and HSV-tk double suicide gene with adenovirus mediation on rectal cancer cells]
[Cytotoxicity of cytosine deaminase and herpes simplex virus thymidine kinase genes in melanoma cells is independent on promoter strength].
[Effects of recombinant adenovirus-mediated double suicide genes on implanted human keloid: experiment with athymic mice]
[Killing effects of PWZL plasmid-mediated double suicide gene on human lens epithelium cells]
[The killing effects of two prodrug sensitivity genes on human pancreatic carcinoma cells PC-2]
Herpes Zoster
Foreword.
Metabolic suicide genes in gene therapy.
HIV Infections
A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians.
APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.
APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals.
ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection.
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
Disruption of the gamma c cytokine network in T cells during HIV infection.
Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.
Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation.
Evaluating the contribution of APOBEC3G haplotypes, on influencing HIV infection in a Zimbabwean paediatric population.
Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors.
HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
HSV-2 Cellular Programming Enables Productive HIV Infection in Dendritic Cells.
Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription.
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Innate immunity in resistance to HIV infection.
Reward versus risk: DNA cytidine deaminases triggering immunity and disease.
Stably expressed APOBEC3F has negligible antiviral activity.
Systems analysis of small signaling modules relevant to eight human diseases.
Understanding the regulation of APOBEC3 expression: Current evidence and much to learn.
[Cellular restriction factors that inhibit human immunodeficiency virus replication: new strategies in antiretroviral therapy].
Homozygous Familial Hypercholesterolemia
Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.
Infections
A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV.
A new delivery system for 5-fluorouracil using prodrug and converting enzyme.
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.
Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove.
Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.
AID and APOBECs span the gap between innate and adaptive immunity.
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
Antibody-Directed Double Suicide Gene Therapy Targeting of MUC1-Positive Leukemia Cells in Vitro and in Vivo.
Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV.
APOBEC Enzymes as Targets for Virus and Cancer Therapy.
APOBEC proteins and intrinsic resistance to HIV-1 infection.
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.
APOBEC3 inhibition of MMTV infection: the role of cytidine deamination versus inhibition of reverse transcription.
Apobec3 may restrict retroviral infection by controlling antibody response.
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
APOBEC3 proteins and reverse transcription.
APOBEC3-mediated restriction of RNA virus replication.
APOBEC3A damages the cellular genome during DNA replication.
APOBEC3A Expression in Penile Squamous Cell Carcinoma.
APOBEC3B deletion and risk of HIV-1 acquisition.
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
APOBEC3G and HIV-1: strike and counterstrike.
APOBEC3G and HIV-1:Strike and Counterstrike.
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.
APOBEC3G expression and HIV-1 infection in Burkina Faso.
APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load.
APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians.
APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.
APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.
APOBEC3G targets human T-cell leukemia virus type 1.
APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells.
APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso.
APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.
APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals.
Association of single nucleotide polymorphisms of APOBEC3G with susceptibility to HIV-1 infection and disease progression among men engaging in homosexual activity in northern China.
Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
Candida albicans Delays HIV-1 Replication in Macrophages.
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
Characterization of Ovine A3Z1 Restriction Properties against Small Ruminant Lentiviruses (SRLVs).
Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.
Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples.
Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.
Correlation of Apolipoprotein B mRNA-editing Enzyme, Catalytic Polypeptide- like 3G Genetic Variant rs8177832 with HIV-1 Predisposition in Pakistani Population.
Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains.
CUL5 and APOBEC3G Polymorphisms are Partially Implicated in HIV-1 Infection and Antiretroviral Therapy in a Brazilian Population.
Current topics in prevention of human T-cell leukemia virus type i infection: NF-kappa B inhibitors and APOBEC3.
Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression.
Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells.
Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G.
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.
Defining HIV-1 Vif residues that interact with CBF? by site-directed mutagenesis.
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.
Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues.
Effect of Vaginal Immunization with HIVgp140 and HSP70 on HIV-1 Replication and Innate and T Cell Adaptive Immunity in Women.
Electrochemical direct detection of DNA deamination catalyzed by APOBEC3G.
Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells.
Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase.
Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.
Expression and regulation of antiviral protein APOBEC3G in human neuronal cells.
Expression of APOBEC3 Lentiviral Restriction Factors in Cats.
Expression of APOBEC3G in kidney cells.
Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection.
Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene.
Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.
Functional Analysis and Structural Modeling of Human APOBEC3G Reveals the Role of Evolutionarily Conserved Elements in HIV-1 and Alu Inhibition.
Functional domains of APOBEC3G required for antiviral activity.
Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses.
Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases.
Fv1 Restriction and Retrovirus Vaccine Immunity in Apobec3-Deficient 129P2 Mice.
Generation of an HIV Resistant T-cell Line by Targeted "Stacking" of Restriction Factors.
HBsAg blocks TYPE I IFN induced up-regulation of A3G through inhibition of STAT3.
Hepatitis B virus X protein is capable of down-regulating protein level of host antiviral protein APOBEC3G.
Heroin use is associated with lower levels of restriction factors and type I interferon expression and facilitates HIV-1 replication.
HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
HIV-1 Vif: a guardian of the virus that opens up a new era in the research field of restriction factors.
HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
Host restriction of lentiviruses and viral countermeasures: APOBEC3 and Vif.
Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.
Human APOBEC3G Can Restrict Retroviral Infection in Avian Cells and Acts Independently of both UNG and SMUG1.
Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription.
Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation.
Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3.
Hypermutation of an ancient human retrovirus by APOBEC3G.
Identification of an arsenic-sensitive block to primate lentiviral infection of human dendritic cells.
IFN-? and Lipopolysaccharide Upregulate APOBEC3 mRNA through Different Signaling Pathways.
Immunoglobulin VH gene diversity and somatic hypermutation during SIV infection of rhesus macaques.
In vitro Assay for Cytidine Deaminase Activity of APOBEC3 Protein.
In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Increased APOBEC3G expression is associated with extensive G-to-A hypermutation in viral DNA in rhesus macaque brain during lentiviral infection.
Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection.
Induction of APOBEC3B cytidine deaminase in HTLV-1-infected humanized mice.
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.
Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo.
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses.
Intrinsic immunity: a front-line defense against viral attack.
Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Macaques as model hosts for studies of HIV-1 infection.
Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.
Mucosal and peripheral Lin- HLA-DR+ CD11c/123- CD13+ CD14- mononuclear cells are preferentially infected during acute simian immunodeficiency virus infection.
Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s.
Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Mutational pressure by host APOBEC3s more strongly affects genes expressed early in the lytic phase of herpes simplex virus-1 (HSV-1) and human polyomavirus (HPyV) infection.
Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.
Natural APOBEC3C variants can elicit differential HIV-1 restriction activity.
Non-lytic Lymphocytes Engineered to Express Virus-specific T-cell Receptors Limit HBV Infection by Activating APOBEC3.
Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response.
Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in Friend virus-infected mice.
Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional BAFF-R.
Perspectives on antiviral drug development.
Pokeweed antiviral protein restores levels of cellular APOBEC3G during HIV-1 infection by depurinating Vif mRNA.
Polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population.
Population stratification of a common APOBEC gene deletion polymorphism.
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Quantifying the antiviral effect of APOBEC3 on HIV-1 infection in humanized mouse model.
Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.
Regulation of HIV-1 Infection in Cells Derived from 1 Purified CD34+ Cells Through Manipulation of APOBEC3G Expression.
Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.
Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly.
Restriction by APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle: ex vivo effects and in vivo "traces" on the murine IAPE and human HERV-K elements.
Restriction of Porcine Endogenous Retrovirus by Porcine APOBEC3 Cytidine Deaminases.
Retraction. Cellular APOBEC3G restricts HIV-1 infection in resting CD4(+) T cells.
Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection.
Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.
Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis.
Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit.
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.
Structural insights for HIV-1 therapeutic strategies targeting Vif.
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.
Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.
THE AKV MURINE LEUKEMIA VIRUS IS RESTRICTED AND HYPERMUTATED BY MOUSE APOBEC3.
The assembly of Vif ubiquitin E3 ligase for APOBEC3 degradation.
The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles.
The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo.
The Cellular Antiviral Protein APOBEC3G Interacts with HIV-1 Reverse Transcriptase and Inhibits Its Function during Viral Replication.
The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53.
The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3.
The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
The Range of Human APOBEC3H Sensitivity to Lentiviral Vif Proteins.
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
The Role of the Antiviral APOBEC3 Gene Family in Protecting Chimpanzees against Lentiviruses from Monkeys.
Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
Vaccinia virus replication is not affected by APOBEC3 family members.
Vif hijacks CBF-? to degrade APOBEC3G and promote HIV-1 infection.
Vif-CBF? interaction is essential for Vif-induced cell cycle arrest.
Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products.
Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages.
Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Vpu and BST2: Still Not There Yet?
[Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1]
[Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].
[The associations between polymorphisms of APOBEC3G and different outcomes of persistent HBV infection]
Influenza, Human
High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity.
Keloid
[Effects of recombinant adenovirus-mediated double suicide genes on implanted human keloid: experiment with athymic mice]
Leukemia
Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove.
All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition.
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
Antibody-Directed Double Suicide Gene Therapy Targeting of MUC1-Positive Leukemia Cells in Vitro and in Vivo.
Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdr1 promoter in mdr1 positive leukemia cells.
APOBEC3 enzymes restrict marginal zone B cells.
APOBEC3 proteins and porcine endogenous retroviruses.
APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair.
APOBEC3G targets specific virus species.
Biochemical and Biological Studies of Mouse APOBEC3.
Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.
Deamination intensity profiling of human APOBEC3 protein activity along the near full-length genomes of HIV-1 and MoMLV by HyperHRM analysis.
Design and selection of toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.
Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene.
Evolution of different antiviral strategies in wild mouse populations exposed to different gammaretroviruses.
Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection.
Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.
Human and murine APOBEC3s restrict replication of koala retrovirus by different mechanisms.
Human APOBEC3 proteins can inhibit xenotropic murine leukemia virus-related virus infectivity.
Human APOBEC3G incorporation into murine leukemia virus particles.
Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3.
In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins.
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.
Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses.
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses.
Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons.
Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Mouse APOBEC3 expression in NIH 3T3 cells mediates hypermutation of AKV murine leukemia virus.
Mouse APOBEC3 interferes with autocatalytic cleavage of murine leukemia virus Pr180gag-pol precursor and inhibits Pr65gag processing.
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.
Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo.
Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.
Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.
Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms.
Repair of APOBEC3G-mutated retroviral DNA in vivo is facilitated by the host enzyme uracil DNA glycosylase 2.
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
Role of APOBEC3 in Genetic Diversity among Endogenous Murine Leukemia Viruses.
Species-specific restriction of apobec3-mediated hypermutation.
Studies on the restriction of murine leukemia viruses by mouse APOBEC3.
THE AKV MURINE LEUKEMIA VIRUS IS RESTRICTED AND HYPERMUTATED BY MOUSE APOBEC3.
The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles.
The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3.
The incorporation of APOBEC3 proteins into murine leukemia viruses.
The multidimensional nature of antiviral innate immunity.
Leukemia, Feline
Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins.
Leukemia, Lymphocytic, Chronic, B-Cell
APOBEC3 signature mutations in chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The growth of K562 human leukemia cells was inhibited by therapeutic neural stem cells in cellular and xenograft mouse models.
Leukemia, T-Cell
APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo.
APOBEC3G targets human T-cell leukemia virus type 1.
Current topics in prevention of human T-cell leukemia virus type i infection: NF-kappa B inhibitors and APOBEC3.
Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.
Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3.
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
Liver Cirrhosis
Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.
[Expression and subcellular localization of APOBEC3G in peripheral blood mononuclear cells and liver tissues of chronic HBV patients]
Liver Neoplasms
Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.
Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.
Gene therapy for murine liver cancer by adenovirus-mediated cytosine deaminase gene.
Gene Therapy with Cytosine Deaminase and Endostatin Fusion Gene Mediated by Endothelial Progenitor Cells in Hepatomas.
Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.
Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-? via their tumor tropism to selectively target human hepatocarcinoma cells.
[Combined gene therapy for murine liver cancer with interleukin-18 and cytosine deaminase genes]
[Expression and subcellular localization of APOBEC3G in peripheral blood mononuclear cells and liver tissues of chronic HBV patients]
Lung Neoplasms
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Combination therapy in A549 cells.
Genetically engineered stem cells expressing cytosine deaminase and interferon-? migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects.
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD).
Single-nucleotide polymorphism of the DNA cytosine deaminase APOBEC3H haplotype I leads to enzyme destabilization and correlates with lung cancer.
The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.
[Combination of ARE and HRE cis- Regulatory Elements Elevates the Activity of Tumor-Specific hTERT Promoter].
Lupus Erythematosus, Systemic
Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus.
Lymphoma
Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma.
APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair.
Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity.
Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Lymphoma, B-Cell
Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma.
The many layers of epigenetic dysfunction in B-cell lymphomas.
Lymphoma, Primary Effusion
Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma.
Malaria
Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells.
Measles
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.
APOBEC3G-Regulated Host Factors Interfere with Measles Virus Replication: Role of REDD1 and Mammalian TORC1 Inhibition.
Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
KDELR2 Competes with Measles Virus Envelope Proteins for Cellular Chaperones Reducing Their Chaperone-Mediated Cell Surface Transport.
Suicide gene?armed measles vaccine virus for the treatment of AML.
The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses.
Medulloblastoma
Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.
Melanoma
A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Augmentation of antitumor effect of adenovirus-mediated CD suicide gene therapy by cotransfer of interleukin 2 gene in melanoma-bearing mice.
Combined therapy of B16(F10) murine melanoma using E. coli cytosine deaminase gene and murine interleukin-4 gene.
Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.
Cytotoxic effects of 5-fluorocytosine on melanoma cells transduced with cytosine deaminase gene.
Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene.
Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy.
PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Prognostic implication and functional annotations of APOBEC3G expression in patients with Melanoma.
Selective augmentation of radiation effects by 5-fluorocytosine on murine B16(F10) melanoma cells transfected with cytosine deaminase gene.
The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors.
Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
[Cytotoxicity of cytosine deaminase and herpes simplex virus thymidine kinase genes in melanoma cells is independent on promoter strength].
[Mesenchymal stem cells expressing cytosine deaminase inhibit growth of murine melanoma B16F10 in vivo].
Melanoma, Experimental
A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Multiple Myeloma
APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Mumps
APOBEC3G-Regulated Host Factors Interfere with Measles Virus Replication: Role of REDD1 and Mammalian TORC1 Inhibition.
The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses.
Nasopharyngeal Carcinoma
A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma.
Neoplasm Metastasis
Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene.
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
APOBEC Enzymes as Targets for Virus and Cancer Therapy.
APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis.
APOBEC3G governs to ensure cellular oncogenic transformation.
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis.
Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-? Against Choriocarcinoma in Xenografted Metastatic Mouse Models.
Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells.
Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells.
Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase.
Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases.
In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.
Inhibitory effect of therapeutic genes, cytosine deaminase and interferon??, delivered by genetically engineered stem cells against renal cell carcinoma.
Integrative analysis of significant RNA-binding proteins in colorectal cancer metastasis.
Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer.
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells.
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes.
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
[Future scope for gene therapy for liver metastasis of colon cancer]
[Vaccination by suicide gene therapy against a model of hepatic metastasis from colon cancer in the rat]
Neoplasms
5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells.
5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene.
A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy.
A high rate of polymerization during synthesis of mouse mammary tumor virus DNA alleviates hypermutation by APOBEC3 proteins.
A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy.
A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
A Phytase-Based Reporter System for Identification of Functional Secretion Signals in Bifidobacteria.
A Protein Antagonist of Activation-Induced Cytidine Deaminase Encoded by a Complex Mouse Retrovirus.
A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.
Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove.
Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity.
Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells.
Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene.
Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity.
Adenovirus-mediated gene transfer in the treatment of pancreatic cancer.
Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts.
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels.
Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference.
Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells.
Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Antitumor Therapy Mediated by 5-Fluorocytosine and a Recombinant Fusion Protein Containing TSG-6 Hyaluronan Binding Domain and Yeast Cytosine Deaminase.
Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53.
APOBEC Enzymes as Targets for Virus and Cancer Therapy.
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
APOBEC-mediated DNA alterations: A possible new mechanism of carcinogenesis in EBV-positive gastric cancer.
APOBEC1 complementation factor facilitates cell migration by promoting nucleus translocation of SMAD3 in renal cell carcinoma cells.
APOBEC1 cytosine deaminase activity on single-stranded DNA is suppressed by replication protein A.
APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion.
APOBEC3 genes: retroviral restriction factors to cancer drivers.
APOBEC3 in papillomavirus restriction, evolution and cancer progression.
APOBEC3 inhibits mouse mammary tumour virus replication in vivo.
APOBEC3 SNPs Predict APOBEC Mutagenesis and Cancer Risk.
APOBEC3-Mediated RNA Editing in Breast Cancer is Associated with Heightened Immune Activity and Improved Survival.
APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
APOBEC3A damages the cellular genome during DNA replication.
APOBEC3B and IL-6 form a positive feedback loop in hepatocellular carcinoma cells.
APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
APOBEC3B Nuclear Localization Requires Two Distinct N-Terminal Domain Surfaces.
APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
APOBEC3B, a molecular driver of mutagenesis in human cancers.
APOBEC3B: Pathological Consequences of an Innate Immune DNA Mutator.
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.
APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma.
APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma.
APOBEC3G governs to ensure cellular oncogenic transformation.
APOBEC3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression.
APOBEC3s: DNA-editing human cytidine deaminases.
APOBEC: A molecular driver in cervical cancer pathogenesis.
Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like family genes activation and regulation during tumorigenesis.
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Gene Expression, RNA Editing, and MicroRNAs Regulation.
Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.
Association of APOBEC3 deletion with cancer risk: A meta-analysis of 26 225 cases and 37 201 controls.
Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers.
Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.
Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells.
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: A partial contribution of gap junctions.
Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.
Cloning, overexpression, and purification of cytosine deaminase from Saccharomyces cerevisiae.
Clostridium spores for tumor-specific drug delivery.
Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice.
Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.
Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine.
Comparison of different methods to assess the cytotoxic effects of cytosine deaminase and thymidine kinase gene therapy.
Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine.
Conformational Switch Regulates the DNA Cytosine Deaminase Activity of Human APOBEC3B.
Conjugation of poly-L-lysine to bacterial cytosine deaminase improves the efficacy of enzyme/prodrug cancer therapy.
Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy.
Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.
Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.
Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer.
Cytosine deaminase producing Clostridium may be used in detection of tumors.
Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.
Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Cytotoxic effects of 5-fluorocytosine on melanoma cells transduced with cytosine deaminase gene.
Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
Design and selection of toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma.
Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies.
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck.
Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model.
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers.
Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells.
Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation.
Enhancement of anti-tumor activity of Newcastle disease virus by the synergistic effect of cytosine deaminase.
Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase.
Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent.
Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions.
Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation.
Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine.
Expression and regulation of antiviral protein APOBEC3G in human neuronal cells.
Expression of APOBEC3G in kidney cells.
Expression of DNA cytosine deaminase APOBEC3 proteins, a potential source for producing mutations, in gastric, colorectal and prostate cancers.
Expression of genes encoding antimicrobial proteins and members of the toll-like receptor/nuclear factor-kappaB pathways in engineered human skin.
Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection.
Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma.
Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs.
Foamy virus vectors for suicide gene therapy.
Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses.
Gene expression profiling of clinical stages II and III breast cancer.
Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element.
Gene therapy in pancreatic cancer.
Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors.
Gene transfer strategies for improving radiolabeled peptide imaging and therapy.
Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from Yeast.
Genetic and in vitro assays of DNA deamination.
Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.
Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients.
Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing.
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases.
High APOBEC1 Complementation Factor Expression Positively Modulates the Proliferation, Invasion, and Migration of Endometrial Cancer Cells Through Regulating P53/P21 Signaling Pathway.
Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples.
Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation.
Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.
Hypoxia imaging predicts success of hypoxia-induced cytosine deaminase/5-fluorocytosine gene therapy in a murine lung tumor model.
Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro.
Hypoxia-induced cytosine deaminase gene expression for cancer therapy.
IFN-? and Lipopolysaccharide Upregulate APOBEC3 mRNA through Different Signaling Pathways.
Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs.
Imaging expression of cytosine deaminase-herpes virus thymidine kinase fusion gene (CD/TK) expression with [124I]FIAU and PET.
Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.
Implantable enzyme capsules for cancer chemotherapy from bakers' yeast cytosine deaminase immobilized on epoxy-acrylic resin and urethane prepolymer.
Improved cytotoxic effects of Salmonella-producing cytosine deaminase in tumour cells.
In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.
In vitro and in vivo effect of 5-FC combined gene therapy with TNF-? and CD suicide gene on human laryngeal carcinoma cell line Hep-2.
In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit.
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study.
Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters.
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection.
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-?B.
Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene.
Infection of Bronchial Epithelial Cells by the Human Adenoviruses A12, B3, and C2 Differently Regulates the Innate Antiviral Effector APOBEC3B.
Inhibition of tumor growth by polyarginine-fused mutant Cytosine deaminase.
Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.
Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.
Interactions of APOBEC3s with DNA and RNA.
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.
Intravenous administration of retroviral replicating vector, toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
KDR promoter can transcriptionally target cytosine deaminase suicide gene to cancer cells of nonendothelial origin.
Live bacteria as anticancer agents and tumor-selective protein delivery vectors.
Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G.
Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells.
LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype.
Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.
Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
Mesenchymal stem cells: A new platform for targeting suicide genes in cancer.
Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells.
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
MicroRNAs regulate APOBEC gene expression.
Moderate sensitivity of mouse mammary tumour virus to inhibition by human APOBEC3G.
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer.
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.
Mouse apolipoprotein B editing complex 3 (APOBEC3) is expressed in germ cells and interacts with dead-end (DND1).
Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
Nanoplex Delivery of siRNA and Prodrug Enzyme for Multimodality Image-Guided Molecular Pathway Targeted Cancer Therapy.
Nanoscale bubble delivered YCD-TK/Cx26 gene therapeutic system suppresses tumor growth by inducing necrosis of tumor tissues in mouse Xenograft bladder cancer models.
Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.
Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy.
Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture.
Nucleotide Weight Matrices Reveal Ubiquitous Mutational Footprints of AID/APOBEC Deaminases in Human Cancer Genomes.
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.
Oncolytic herpes simplex virus vectors for cancer virotherapy.
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
Overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-related hepatocellular carcinoma.
p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Pancancer analysis identifies prognostic high-APOBEC1 expression level implicated in cancer in-frame insertions and deletions.
Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations.
Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier.
Photodynamic therapy-driven induction of suicide cytosine deaminase gene.
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism.
Powerful mutators lurking in the genome.
Prodrug converting enzyme gene delivery by L. monocytogenes.
Prognostic implication and functional annotations of APOBEC3G expression in patients with Melanoma.
Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy.
Protein-Programmed Accumulation of Yeast Cytosine Deaminase in Cancer Cells in Response to Mock-Hypoxia.
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Radiation treatment decreases bone cancer pain through direct effect on tumor cells.
Radiosensitization and Anti-tumour Effects of Cytosine Deaminase and Thymidine Kinase Fusion Suicide Gene in Human Adenoid Cystic Carcinoma Cells.
Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.
Re: Association of Germline Variants in the APOBEC3 Region with Cancer Risk and Enrichment with APOBEC-Signature Mutations in Tumors.
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Redesigned Escherichia coli cytosine deaminase: a new facet of suicide gene therapy.
Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver.
Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy.
Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.
Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
Selective inhibition of APOBEC3 enzymes by single-stranded DNAs containing 2'-deoxyzebularine.
Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy.
Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Simultaneous detection of 5-fluorocytosine and 5-fluorouracil in human cells carrying CD/5-FC suicide gene system by using capillary zone electrophoresis.
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.
Structural Characterization of a Minimal Antibody against Human APOBEC3B.
Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B.
Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression.
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.
Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus.
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-? via their tumor tropism to selectively target human hepatocarcinoma cells.
Systems analysis of small signaling modules relevant to eight human diseases.
Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.
Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Targeted Tumor Therapy With a Fusion Protein of an Antiangiogenic Human Recombinant scFv and Yeast Cytosine Deaminase.
The APOBEC3 genes and their role in cancer: insights from human papillomavirus.
The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead.
The PKC/NF-?B signaling pathway induces APOBEC3B expression in multiple human cancers.
The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model.
The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.
The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.
The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization.
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors.
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.
Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
Transduction of yeast cytosine deaminase mediated by HIV-1 Tat basic domain into tumor cells induces chemosensitivity to 5-fluorocytosine.
Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability.
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Treatment of human tumor cells by combine gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and bacterial cytosine deaminase suicide gene.
Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes.
Treatment of Tumor in Mice by Oral Administration of Cytosine Deaminase Gene Carried in Live Attenuated Salmonella.
Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.
Understanding the regulation of APOBEC3 expression: Current evidence and much to learn.
Understanding the structural details of APOBEC3-DNA interactions using graph-based representations.
Understanding the Structure, Multimerization, Subcellular Localization and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H.
Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma.
Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy.
Vascular targeting: a potential additional anti-cancer treatment.
Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts.
When defense turns into attack: Antiviral cytidine deaminases linked to somatic mutagenesis in HPV-associated cancer.
Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
Zinc enhancement of cytidine deaminase activity highlights a potential allosteric role of loop-3 in regulating APOBEC3 enzymes.
[Anaerobic bacteria as a gene delivery system for breast cancer therapy]
[Antitumor activity of the recombinant rClone30-CD/5-FC system].
[Antitumor effect of combined therapy with adenovirus-mediated CD suicide gene and interleukin 2 gene transfer and its immunological mechanism]
[Apoptosis induced by transferring cytosine deaminase suicide gene into kinds of cancer cells with novel polyamidoamine dendrimers].
[Combination of ARE and HRE cis- Regulatory Elements Elevates the Activity of Tumor-Specific hTERT Promoter].
[Future scope for gene therapy for liver metastasis of colon cancer]
[Hypoxia in malignant tumors the target for clostridial therapeutic gene strategies]
[Vaccination by suicide gene therapy against a model of hepatic metastasis from colon cancer in the rat]
[X-ray combined with cytosine deaminase suicide gene therapy enhances killing of colorectal carcinoma cells in vitro]
Neoplasms, Germ Cell and Embryonal
Mouse apolipoprotein B editing complex 3 (APOBEC3) is expressed in germ cells and interacts with dead-end (DND1).
Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability.
Neoplasms, Squamous Cell
Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.
Newcastle Disease
Enhancement of anti-tumor activity of Newcastle disease virus by the synergistic effect of cytosine deaminase.
Obesity
Induction of body weight loss through RNAi-knockdown of APOBEC1 gene expression in transgenic rabbits.
Osteolysis
Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture.
Radiation treatment decreases bone cancer pain through direct effect on tumor cells.
Ovarian Neoplasms
APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women.
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.
APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma.
Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter.
Procaspase-3 enhances the in vitro effect of cytosine deaminase-thymidine kinase disuicide gene therapy on human ovarian cancer.
Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.
The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
[Anticancer effects of cytosine deaminase gene/5-fluorocytosine therapies to ovarian cancer in vivo]
[Gene therapy for ovarian cancer by adenovirus-mediated transduction of cytosine deaminase gene in vitro]
Pancreatic Neoplasms
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
Apoptosis induced by 5-flucytosine in human pancreatic cancer cells genetically modified to express cytosine deaminase.
Killing effects of cytosine deaminase gene mediated by adenovirus vector on human pancreatic cancer cell lines in vitro.
Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene.
Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes.
Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter.
Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression.
The virus-induced protein APOBEC3G inhibits anoikis by activation of Akt kinase in pancreatic cancer cells.
Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy.
Papilloma
Heat-Induced Editing of HPV Genes to Clear Mucocutaneous Warts?
p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Papillomavirus Infections
APOBEC3 regulates keratinocyte differentiation and expression of Notch3.
Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.
HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples.
Role of the host restriction factor APOBEC3 on papillomavirus evolution.
Peripheral Vascular Diseases
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Peritoneal Neoplasms
Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis.
Persistent Infection
Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.
Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.
[The associations between polymorphisms of APOBEC3G and different outcomes of persistent HBV infection]
Prostatic Neoplasms
Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.
Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice.
Downregulation of APOBEC3G by xenotropic murine leukemia-virus related virus (XMRV) in prostate cancer cells.
Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells.
Expression of DNA cytosine deaminase APOBEC3 proteins, a potential source for producing mutations, in gastric, colorectal and prostate cancers.
Hypoxia theranostics of a human prostate cancer xenograft and the resulting effects on the tumor microenvironment.
Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer.
In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit.
Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Psoriasis
APOBEC3 regulates keratinocyte differentiation and expression of Notch3.
Rectal Neoplasms
Combined liposome-mediated cytosine deaminase gene therapy with radiation in killing rectal cancer cells and xenografts in athymic mice.
[Antitumor effects of cytosine deaminase and HSV-tk double suicide gene with adenovirus mediation on rectal cancer cells]
[Three-pronged approach to treat rectal cancer: liposome transfer cytosine deaminase gene, ionizing radiation and dendritic cells]
Retroviridae Infections
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.
Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Deaminase-Dead Mouse APOBEC3 is an
Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari.
Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance.
IFN-? treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.
Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.
In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins.
Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection.
Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.
Loci Polymorphisms of the APOBEC3G Gene in HIV Type 1-Infected Brazilians.
Repression of porcine endogenous retrovirus infection by human APOBEC3 proteins.
Rhabdomyosarcoma
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.
Rubella
Unusual nucleotide content of Rubella virus genome as a consequence of biased RNA-editing: comparison with Alphaviruses.
Sarcoma
Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
Radiation treatment decreases bone cancer pain through direct effect on tumor cells.
Sarcoma, Avian
Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins.
Simian Acquired Immunodeficiency Syndrome
APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host.
Squamous Cell Carcinoma of Head and Neck
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response.
Starvation
Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
Stomach Neoplasms
APOBEC-mediated DNA alterations: A possible new mechanism of carcinogenesis in EBV-positive gastric cancer.
Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma.
Promoter selection for the cytosine deaminase suicide gene constructs in gastric cancer.
Stem cells with fused gene expression of cytosine deaminase and interferon-? migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use.
The roles of APOBEC3B in gastric cancer.
Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors.
Superinfection
The effects of MAPK p38? on AZT resistance against reactivating HIV-1 replication in ACH2 cells.
Thyroid Carcinoma, Anaplastic
Antithyroid cancer effects of human neural stem cells expressing therapeutic genes on anaplastic thyroid cancer cells.
Thyroid Neoplasms
Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine.
Tumor Virus Infections
Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection.
Urinary Bladder Neoplasms
APOBEC3B Activity Is Prevalent in Urothelial Carcinoma Cells and Only Slightly Affected by LINE-1 Expression.
Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Uterine Cervical Neoplasms
Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells.
APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity.
APOBEC3A Expression in Penile Squamous Cell Carcinoma.
APOBEC: A molecular driver in cervical cancer pathogenesis.
Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.
Vaccinia
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases.
Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus.
Vaccinia virus replication is not affected by APOBEC3 family members.
Vectorized Gene Therapy of Liver Tumors: Proof of Concept of TG4023 (MVA-FCU1) in Combination with Flucytosine.
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.
Vesicular Stomatitis
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Viremia
APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.
Fv1 Restriction and Retrovirus Vaccine Immunity in Apobec3-Deficient 129P2 Mice.
Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in Friend virus-infected mice.
Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional BAFF-R.
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
Virus Diseases
A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
AID and APOBEC deaminases: balancing DNA damage in epigenetics and immunity.
Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator.
An overview of cytidine deaminases.
APOBEC3 genes: retroviral restriction factors to cancer drivers.
APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells.
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma.
Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection.
Expression of APOBEC3G in kidney cells.
Genetic and in vitro assays of DNA deamination.
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer.
Human APOBEC3 Variations and Viral Infection.
Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia.
In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models.
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo.
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
Non-lytic Lymphocytes Engineered to Express Virus-specific T-cell Receptors Limit HBV Infection by Activating APOBEC3.
Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Recurrent Loss of APOBEC3H Activity during Primate Evolution.
Restriction of feline retroviruses: lessons from cat APOBEC3 cytidine deaminases and TRIM5alpha proteins.
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Structural Characterization of a Minimal Antibody against Human APOBEC3B.
The APOBEC3 family of retroelement restriction factors.
The Battle between Retroviruses and APOBEC3 Genes: Its Past and Present.
The inhibition of hepatitis B virus by APOBEC cytidine deaminases.
The role of cytidine deaminases on innate immune responses against human viral infections.
The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.
Understanding the regulation of APOBEC3 expression: Current evidence and much to learn.
Vaccinia virus replication is not affected by APOBEC3 family members.
[Mechanisms of interaction between HIV and Mycoplasma arginini in vitro]
Whooping Cough
CCR6 ligands inhibit HIV by inducing APOBEC3G.
Wilms Tumor
[Therapeutic effect of 5-fluorocytosine on cytosine deaminase gene transduced Wilms' tumor xenograft in nude mice]
Zoonoses
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.